Aktienanalyse zu Cogent Biosciences Inc (COGT)COGTCogent Biosciences Inc

Cogent Biosciences, Inc. is a clinical-stage biotechnology company. It is focused on developing precision therapies for genetically defined diseases. Its approach is to design rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its advanced program is bezuclastinib, also known as CGT9486, a highly selective tyrosine kinase inhibitor that is designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. KIT D816V is responsible for driving systemic mastocytosis (SM), a serious and rare disease caused by unchecked proliferation of mast cells. The Company has on-going Phase I studies of its CNS-penetrant, selective mutant ErbB2 inhibitor and its potential best-in-class, wild-type-sparing, PI3Ka inhibitor. In addition, the Company’s research team is developing a portfolio of novel targeted therapies to help patients fighting serious, genetically driven diseases targeting mutations in KRAS and JAK2. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Cogent Biosciences Inc is a good buy right now, trading at $31 with a strong upside potential. Analysts have set a price target of $62, indicating a potential upside of 100% from the current price. Additionally, the company has recently submitted a New Drug Application for Bezuclastinib, which could significantly boost its market position. However, the main risk is the negative earnings trend, with an EPS of -0.52 reported in the last quarter.

3 analysts cover COGT: 3 rate it Buy, 0 Hold and 0 Sell. The average price target is 50.36.